|

Best Available Therapy (BAT) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: alemtuzumab (Campath®, Lemtrada®), cladribine (Mavenclad®), natalizumab (Tysabri®), ocrelizumab (Ocrevus®), ofatumumab (Kesimpta®) +2 more

Pipeline

Phase 3: 1

Top Sponsors

  • National Institute of Allergy and Infectious Diseases (NIAID)1

Indications

  • Secondary Progressive Multiple Sclerosis1
  • Relapsing Remitting Multiple Sclerosis1
  • Relapsing Multiple Sclerosis1
  • Multiple Sclerosis1

Palo Alto, California1 trial

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Stanford Multiple Sclerosis Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.